0.72
+1.73%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Metagenomi Therapeutics
From its filings with the US Securities and Exchange Commission
Metagenomi Therapeutics is based in Emeryville, California. Its shares trade on Nasdaq under the ticker MGX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $25.2m and a net loss of $87.9m. At that date it held total assets of $221.1m and shareholders' equity of $158.6m.
We are an in vivo genome editing company capitalizing on our proprietary technologies to create curative genetic medicines for patients. We were founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel gene editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. We leverage machine learning and artificial intelligence to enhance our signature gene editing systems. In late 2025, we made the decision to strategically reprioritize our pipeline and discovery efforts to focus our resources on driving forward our lead programs that utilize our most advanced, signature gene-editing capabilities with the highest probability of success while maintaining financial discipline to drive sustainable growth and long-term value. We increased our focus on high-value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways to accelerate programs with the potential to deliver therapeutic benefits of gene editing to patients.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Feb 2024
- Employees
- 223
- Website
- metagenomi.co ↗
- Head office
- 5959 HORTON STREET, EMERYVILLE, CA, 94608
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Brian ThomasChairman of the Board, Chief Executive Officer, Co-Founder, since 2024$6.1m
- Dr. Jian IrishPresident, Chief Operating Officer, Director, since 2021$3.8m
- Ms. Pamela WapnickChief Financial Officer$3.6m
- Mr. Matthew WeinSenior Vice President, Head of Legal, Compliance Officer and Corporate Secretary
- Dr. Sarah NoonbergChief Medical Officer$2.0m
- Dr. Willard DereLead Independent Director$663,435
- Dr. Laurence ReidDirector
- Mr. Eric BjerkholtIndependent Director
- Dr. Juergen EckhardtIndependent Director, since 2024$660,221
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 27
- Environment
- 27
- Social
- 31
- Governance
- 23
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Metagenomi Therapeutics Inc employs 223 full-time employees in the US Biotechnology sector.
- The company's comprehensive metagenomics derived toolbox targets any site in the human genome precisely.
- Its genome editing toolbox includes programmable nucleases, base editors, and CRISPR-associated transposases (CASTs).
Weaknesses
- Metagenomi Therapeutics Inc has only 223 employees in the US Biotechnology sector.
- The company's IPO on February 9, 2024, is recent and unproven.
- Its platform requires rapid development to prove efficacy in genetic medicine.
Opportunities
- The US Biotechnology sector offers growth for Metagenomi's metagenomics derived toolbox.
- Metagenomi's genome editing toolbox can target diverse disease targets in the Health Care industry.
- The company can expand its modular toolbox for site-specific genome interactions.
Threats
- The US Biotechnology sector faces intense competition from established players.
- Metagenomi's recent IPO may face market volatility in 2024.
- The Health Care industry requires extensive regulatory approvals for genetic medicine.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.